Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs ONEOK Inc. Common Stock (OKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs ONEOK Inc. Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while ONEOK Inc. Common Stock trades at $92.29 (market cap $58.87B). The key difference: ONEOK Inc. Common Stock is far larger — about 6.6× Kymera Therapeutics Inc. Common Stock's market cap, and ONEOK Inc. Common Stock pays a 4.58% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and ONEOK Inc. Common Stock for 5 Days on average.
| KYMR | OKE | |
|---|---|---|
Market Cap | $8.87B | $58.87B |
Volume | 779,107 | 2,504,054 |
Sector | Health | Energy |
52-Week High | $127.31 | $97.51 |
52-Week Low | $55.80 | $64.31 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $8.26B | $91.73B |
Dividend Yield | — | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ONEOK (OKE) trades at $93.38, up 1.48% with a bullish technical outlook and strong fundamental performance. The stock shows solid valuation metrics with P/E of 16.13 and P/S of 1.5, supported by $33.63B revenue and $3.39B net income in 2025. Recent acquisition of Brazos Midstream's assets for $4.425B expands Permian Basin presence, while quarterly dividends remain steady at $1.07 per share.
Outlook remains positive with analyst consensus target of $98.55 (5.5% upside) and no sell ratings. Key risks include integration of recent acquisition and commodity price exposure. Earnings beat expectations in 2 of last 3 quarters, with Q3 2026 results due October 27 providing next catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About ONEOK Inc. Common Stock
ONEOK operates energy infrastructure for natural gas, natural gas liquids, and crude oil. Its assets include pipelines, processing facilities, storage, and related services.
Read more on OKE →
